Ultrahigh-throughput Identification of Molecular Targets of Natural Products

天然产物分子靶标的超高通量鉴定

基本信息

批准号：
9263893
负责人：
DAOJING WANG
金额：
$ 81.13万
依托单位：
NEWOMICS, INC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-06-01 至 2019-09-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9263893
关键词：
Binding Bioinformatics Biological Biological Assay Biological Availability Biomedical Research Blood Blood Cells Blood specimen Businesses Cell Line Clinical Research Collaborations Communities Coupled Crude Extracts Databases Development Diabetes Mellitus Diabetic mouse Diagnosis Disease Progression Drug Kinetics Foundations Human KRAS2 gene Laboratories Libraries Liquid Chromatography Malignant Neoplasms Mass Spectrum Analysis Microfluidic Microchips Mississippi Molecular Target Monitor Natural Products Pathway interactions Performance Pharmaceutical Preparations Phase Plants Preparation Proteins Proteome Proteomics Publishing Reporting Resveratrol Sampling Sensitivity and Specificity Serum Albumin Silicon Small Business Innovation Research Grant Source Spectrometry, Mass, Electrospray Ionization Technology Therapeutic Effect Tissues Toxic effect Universities Validation Vendor Walkers analog base commercialization drug development drug discovery high throughput screening in vivo industry partner innovation insight mass spectrometer metabolome metabolomics mouse model next generation novel therapeutics operation public health relevance research and development response screening therapeutic evaluation treatment response

项目摘要

DESCRIPTION (provided by applicant): Natural products are rich sources for potential drugs. To accelerate drug discovery from natural products, it is imperative to identify their molecular targets, and mechanistically elucidate their bioavailability, toxicity, and therapeutic effects. However, there remain several challenges in the field. Among them, there is currently no technical platform that could perform mechanistic studies from the "hits" to "leads" using the small volumes of samples that are typically encountered in quantitative high-throughput screening or obtained from biological and clinical studies. To tackle these challenges and in response to RFA-AT-16-003, Newomics Inc. proposes to complete development of its product, a multiomics platform for high-throughput and high-content bioassays of natural products. The Phase II project is built upon the promising results generated from our Phase I project. In Phase I, we have developed ESI-MS assays to screen the interactions between molecular targets and natural products from libraries with different complexity. In Phase II, we will complete development of multiomics assays for commercialization, through working closely with industry partners, academic collaborators, and business consultants. Once developed, Newomics' Omics-chip may become a universal platform for high-throughput identification of molecular targets of natural products in the blood or other tissues, and lay a new foundation for drug discovery and development.

描述（由适用提供）：天然产品是潜在药物的丰富来源。为了加速天然产物的药物发现，必须确定其分子靶标，并机械阐明其生物利用度，毒性和治疗作用。但是，该领域仍然存在一些挑战。其中，目前尚无技术平台可以使用通常在定量高通量筛选或从生物学和临床研究中获得的少量样品进行机械研究。为了应对这些挑战并回应RFA-AT-16-003，Newomics Inc.完成了其产品开发的提议，该产品是一种用于高通量和高含有天然产品的多组学平台。第二阶段项目建立在我们第一阶段项目产生的承诺结果之上。第一阶段，我们已经开发了ESI-MS评估，以筛选出不同复杂性的库中分子靶标与天然产物之间的相互作用。在第二阶段，我们将通过与行业合作伙伴，学术合作者和商业顾问紧密合作来完成商业化的多图评估。一旦开发，新来者的Omics-Chip可能成为对血液或其他时间天然产物分子靶标的高通量鉴定的通用平台，并为药物发现和开发奠定了新的基础。